Phase I Evaluation of RO7589831 Monotherapy and Combined with Pembrolizumab in Patients with Advanced Solid Tumors

The primary objective of this study is to evaluate the safety and tolerability of **RO7589831** when administered alone and in combination with **pembrolizumab** in participants with **advanced solid tumors**. This is clinically relevant as it aims to determine the potential of RO7589831 as a therapeutic option for patients with these malignancies, potentially improving treatment outcomes and expanding therapeutic strategies. No secondary objectives are provided in the available data.

The clinical trial involves a total of **3 participants** diagnosed with **advanced solid tumors**. The study population includes both male and female subjects, with an age range spanning from **18 to 64 years**. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the safety and efficacy of **RO7589831** alone and in combination with **Pembrolizumab** in participants with **advanced solid tumors**. This is a Phase I trial, which is characterized by its exploratory nature, focusing on determining the appropriate dosage and assessing the initial safety profile of the investigational drug. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from the recruitment start date on January 11, 2024, to the anticipated end date on April 12, 2027.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation, including medical history, physical examination, and laboratory tests. Following successful screening, participants will be randomized into different study arms. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health status, drug tolerance, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment.

The expected length of participant involvement in the trial is approximately three years, contingent upon individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any protocol deviations that compromise the integrity of the trial. Participants will be closely monitored throughout the study to ensure their safety and the collection of high-quality data.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of January 11, 2024, and an estimated end date of April 12, 2027. The efficacy assessment will be conducted using predefined parameters or endpoints, although specific details regarding these endpoints are not provided in the available data. The trial will follow a systematic approach to measure, collect, and analyze efficacy data at designated timepoints throughout the study duration. The methods and tools for efficacy assessment are not specified in the provided information. The trial will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.